Company

Upstream Bio, Inc.

Upstream Bio develops antibody therapies for inflammatory and allergic diseases.

About

Upstream Bio's lead clinical-stage program is a monoclonal antibody that inhibits the TSLP receptor. It is developing treatments for conditions including severe asthma. Founded in 2021, the company is based in Massachusetts, US. It raised USD 255 million in an IPO in October 2024.

4Funding rounds

10Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in